Page 8 - Diabetes

Are sugar alternatives actually healthy? Here's what experts suggest

On World Diabetes Day, Business Standard spoke with experts to demystify sugar substitutes that have found a way into our diet

Study finds how AI helps to predict diabetes complications in patients

In the United States, more than 37 million individuals have diabetes, yet many of them don't receive immediate treatment, which can result in expensive or even fatal consequences

More uncovered on link between late-night eating and weight gain, diabetes

Scientists have uncovered details of the metabolism of late-night eating associated with weight gain and diabetes, according to a study. While the connection between time, sleep and obesity is well-known, it is misunderstood because research showed that overnutrition can disrupt circadian rhythms and change fat tissue, the study by a team of researchers from the Northwestern University stated. It also showed that energy release may be the molecular mechanism through which the internal clocks of human beings control energy balance. From this understanding, the scientists also found that daytime is the ideal time in the light environment of the Earth's rotation when it is most optimal to dissipate energy as heat. These findings, published in the journal Science, have broad implications from dieting to sleep loss and the way patients who require long-term nutritional assistance are fed. "It is well known, albeit poorly understood, that insults to the body clock are going to be insult

Physical inactivity may cost the world $300 bn between 2020 and 2030: WHO

Around 500 mn people will develop heart disease, obesity, diabetes or other non-communicable diseases (NCDs) due to physical inactivity, WHO's 'Global Status Report on Physical Activity 2022' says

Researchers develop new 3d technique to revolutionise diabetes treatment

A new bandage treatment, known as a scaffold, to treat diabetic foot ulcers, which is cost-effective while improving patient outcomes, has been designed by researchers at Queen's University Belfast

Covid-19 linked with higher risk of type 1 diabetes in young people: Study

Children and adolescents infected with COVID-19 show a substantially higher risk of developing type 1 diabetes (T1D), according to a study of over 1 million patients aged 18 and younger. The findings, published recently in the journal JAMA Network Open, showed a 72 per cent increase in new diagnoses of T1D in younger COVID-19 patients in the six months following their diagnosis. However, the research emphasised that it is unclear whether COVID-19 triggers new onset of T1D. "Type 1 diabetes is considered an autoimmune disease," said Pamela Davis, a professor at the Case Western Reserve School of Medicine, US, and corresponding author of the study. "It occurs mostly because the body's immune defenses attack the cells that produce insulin, thereby stopping insulin production and causing the disease. COVID has been suggested to increase autoimmune responses, and our present finding reinforces that suggestion," Davis said. The team analysed the de-identified electronic health records o

Diabetes burden: India lost 45 years of healthy life per person in 2021

By 2040, Type 1 diabetes cases to increase by 116% in India, says Lancet study

India among top 10 countries with most cases of Type 1 diabetes: Study

An estimated 8.4 million people were living with Type 1 Diabetes across the globe in 2021, and India was among the top ten countries with highest prevalence of the disease, according to a modelling study published in The Lancet Diabetes & Endocrinology journal. This number is predicted to increase to 13.5-17.4 million people living with Type 1 Diabetes (T1D) by 2040, the resaerchers said. "Given that prevalence of people with T1D is projected to increase in all countries to up to 17.5 million cases in 2040, our results provide a warning for substantial negative implications for societies and healthcare systems," said Professor Graham Ogle, one of the authors of the study, from the University of Sydney, Australia. "There is an opportunity to save millions of lives in the coming decades by raising the standard of care for T1D and increasing awareness of the signs and symptoms of T1D to enable a 100 per cent rate of diagnosis in all countries," Ogle said. Researchers modelled data on

Govt launches diabetes drug Sitagliptin, its combinations at Rs 60 per pack

The government on Friday launched diabetes drug Sitagliptin and its combinations at rates as low as Rs 60 per pack of ten, which will be sold at generic pharmacy stores, Janaushadhi Kendras. The Pharmaceuticals & Medical Devices Bureau of India (PMBI) has included new variants of Sitagliptin and its combination across its Jan Aushdhi Kendras, the Ministry of Chemicals and Fertilisers said in a statement. The maximum retail price for a pack of ten Sitagliptin phosphate tablets 50 mg is Rs 60, while the same for Sitagliptin phosphate tablet 100 mg is Rs 100. Combination of Sitagliptin and Metformin Hydrochloride tablets of 50mg/500mg is priced at Rs 65 for a pack of ten and Sitagliptin Metformin hydrochloride tablets of 50mg/1000mg strength comes for Rs 70 for the same quantity. "All these variants are available at 60 per cent to 70 per cent lesser prices than branded variants as they are available in price band of Rs 162 to Rs 258 at other medical stores," the statement said. PMBI

Controlling blood sugar level can predict risk to type 1 diabetics

New research states that blood sugar level should be lower than 53 mmol/mol (7%) to avoid health complications

New diabetes drug achieves blood sugar, weight targets faster: Research

T2D is a chronic and progressive condition in which the body does not make or use insulin normally, leading to high levels of glucose in the blood

Control of blood sugar in mothers with diabetes better for infants: Study

Research led by Caroline Crowther of the University of Auckland, New Zealand, and a team, the findings were published in the journal PLOS Medicine

Pricing regulator closely watching prices of diabetes drug going off patent

Regulator looking to cap prices of Sitagliptin, Linagliptin and combinations

Zydus Life launches generic version of Sitagliptin for type 2 diabetes

Zydus Lifesciences Ltd on Friday said it has launched the generic version of sitagliptin in India under the brand names Sitaglyn and Siglyn to address type 2 diabetes.

Going off-patent, key diabetes drug likely to get 50-70% cheaper

Merck's Sitagliptin set to lose patent this month; around 200 brands from 50 firms may enter the market

US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients

On Tuesday, the CDC, citing case reports and concerns that relapsed patients could spread the virus, issued its advisory that Paxlovid users should isolate for a second five days if symptoms rebound

Tech firm MFine helps people monitor blood pressure, glucose on smartphones

MFine has democratised health care at home by bringing these solutions on to devices that are more ubiquitous and affordable than wearables

Long Covid-induced diabetes, depression can be treated by exercise: Study

Though no medically recognized treatment exists for Long Covid, a study suggests that exercise might break cycle of inflammation that develops diabetes and depression months after a person recovers

Zydus gets regulator nod to market generic diabetes drug in American

Zydus Group on Wednesday said it has received final approval from the US health regulator to market diabetes medication Dapagliflozin tablets in the American market. The drug maker has received final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 5 mg and 10 mg. Dapagliflozin is used with a proper diet and exercise programme to control high blood sugar in people with type 2 diabetes. The drug also lowers the risk of heart failure in adults with type 2 diabetes with heart disease. It is also used to lower the risk of further worsening of kidney disease, end-stage kidney disease (ESKD), death due to cardiovascular disease, and hospitalisation for heart failure in adults with chronic kidney disease. Dapagliflozin works by increasing the removal of sugar by kidneys. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad, Zydus Group stated. The group now has 328 approvals and has so far fi

Pharma company Abbott ties up with health tech firms for diabetes care

Abbott on Tuesday said it has tied up with health-tech firms like BeatO, Sugar.fit, PharmEasy, GOQii, 1MG and Zyla for diabetes care